十二味地黄汤对高血压患者早期肾损害的临床干预研究

《十二味地黄汤对高血压患者早期肾损害的临床干预研究》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、提要目的：观察十二味地黄汤对高血压患者早期肾损害的临床干预研究。方法：根据纳入病例标准，选取60例高血压伴早期肾损害患者，随机分为治疗组和对照组。对照组30例，给予常规西药治疗；治疗组30例，在常规西药治疗基础上加服十二味地黄汤，一日一剂，二次分服，8周后进行临床疗效评定。分别于治疗前、后行血压测量，尿微量蛋白，肾功能等实验室检查，观察患者血压、症状、体征及肾功能水平在治疗前后的变化，从而评判其疗效及安全性。结果：治疗8周后，临床研究显示治疗组在肾功改善积分、中医证候总疗效方面优于对照组（P＜0.05）；治疗

2、后，治疗组肾功改善改善优于对照组（P＜0.05）。结论：十二味地黄汤对高血压患者早期肾损害方面有显著保护作用。关键词十二味地黄汤；高血压患者；肾损害；临床研究ToObservetheClinicalEfficacyofShiErWeiDiHuangDecoctionintheEarlyStageHypertensiveNephropathySpecialty:InternalMedicineofTraditionalChineseMedicineAuthor:SunNingningTutor:Prof.LuX

3、iaohuiAbstractObjective:Toobservetheclinicalefficacyofshierweidihuangdecoctionintheearlystagehypertensivenephropathy.Methods:60casesoftheearlystagehypertensivenephropathywererandomlydividedintotreatmentgroupandcontrolgroup,thetreatmentgroupof30patientstreat

4、edwithroutinetreatmentandshierweidihuangdecoction，andthecontrolgroupof30patientsonlytreatedwithroutinetreatment.Beforetreatment,respectively,underwentbloodpressuremeasurement,urinetraceprotein,andrenalfunctionlaboratorytests,theobservedbloodpressurechanges,

5、symptoms,signsofchangeofthelevelofrenalfunctionbeforeandaftertreatment,inordertojudgetheirefficacyandsafety.Results:After4weeksoftreatment,clinicalstudieshaveshowntreatmentgroupimprovedinrenalfunctionpoints,designatethetotaleffectofTCMsyndromethanthecontrol

6、group(P<0.05).Theclinicalstudyshowedthatthetreatmentgroupwasbetterthanthecontrolgroupintheearlystagehypertensivenephropathy.Conclusion:thetreatmentofshierweidihuangdecoctionhasabettercurativeeffectfortheearlystagehypertensivenephropathypatientKeywordshypert

7、ensive；shierweidihuangdecoction；Clinicstudy目录引言...............................................................................................................................0临床研究..............................................................................

8、.................................................3一、研究对象及病例来源...................................................................................................3二、病例选择标准................................